I held some 150c options through data (even though you should never hold through data, no matter what) just to keep a toe in the water and see how it all plays out.

I am no scientist, but they seem to have done what they set out to do - show improved cognition at 9 months of treatment on simulfilam.  It was 18% vs 10% in the 6 month readout.

There were massive expectations built into this event and data readout.  I think, no matter what, it was going to be a sell the news event.

I don't think SAVA's story is over.  Far from it.  Unless I'm reading the data incorrectly, there's a lot of upside for the company here (valuations aside).  If the data is real, I don't see how a bigger pharma doesn't come in and either buy them or do a partnership (most likely).  

I've still got three weeks left on the options, so I'm going to sit tight and see if there's an extra scene in the credits.

Basically, their treatment repairs this altered filamin-A found in the brain with AD patients. After 28 days, their treatment repairs 48% of these altered filamin-A things. This was new data released today. 

So Thursday's data will show whether their treatment shows cognitive improvement in AD patients using the Alzheimer's scale. This is a 9 month data report. The 6 month showed a 10% increase in cognition. So this 9 month readout, has to show improvement from that 6 month mark. And if it shows improvement, that means they are successfully targeting the correct thing with this altered filamin-A treatment. No company has shown any improvements at the 9 month mark.

SAVA is proving a wild, exciting ride going into the AAIC conference.  We hit $130! 

The countdown to 9 month data release and SavaDx begins..... 🤞

We had a huge Monday on that news, +10.  Tuesday we gave it all back, -12.  Unexpected on both days, really.  

I closed (for a tiny profit) those covered calls that went the wrong way on me - so that was a good result.  I shouldn't have closed them so fast, but I wasn't expecting any of this, so I guess I was sort of flying blind in general.

I added more SAVA today at 77.67.  I intend to write some higher price covered calls on the next pop.

One of the things that I think is being overlooked here (at least it was by me) is SavaDx

Update on SavaDx
SavaDx is an investigational diagnostic candidate to detect Alzheimer’s disease with a simple blood test. SavaDx was evaluated for its ability to detect treatment effects of simufilam versus placebo in a randomized, controlled study completed in 2020. This was a Phase 2b study that enrolled 64 patients with Alzheimer’s disease. The SavaDx clinical dataset will be presented at AAIC the week of July 26-30th.

I wrote some 90c cover calls on this last week, thinking it'd be weeks before it would hit 90.  I was wrong.  It hit it in 3 days.

They put out a very helpful PR today confirming data presentation.  I'll put it on the DD thread.